Gymnema for Cholesterol — Lipid Lowering in Diabetic Dyslipidemia, Insulin Sensitization & Bile-Acid Binding

Gymnema is not a primary lipid-lowering agent. Patients with severe hypercholesterolemia, familial hyperlipidemia, or established atherosclerotic cardiovascular disease require evidence-based pharmacological intervention (statins, ezetimibe, PCSK9 inhibitors, bempedoic acid). What gymnema does produce, in the controlled trials in diabetic patients, is meaningful modest lipid improvement: total cholesterol down 10-15%, LDL down by a similar magnitude, triglycerides down 15-25%, and HDL up 5-10%. The mechanism is two-pronged. The dominant indirect pathway is insulin sensitization: improved insulin signaling suppresses hepatic de novo lipogenesis, which is the central driver of the elevated triglycerides characteristic of diabetic dyslipidemia and metabolic syndrome. The smaller direct pathway is bile-acid binding by saponin fractions in the gut, which interrupts the enterohepatic recycling of bile acids and forces the liver to use cholesterol to synthesize replacements. The combined effect is smaller than berberine and considerably smaller than a statin, but is clinically meaningful in patients who are using gymnema for primary diabetes management and getting cholesterol benefits as a bonus.

Table of Contents

1. Diabetic Dyslipidemia — The Lipid Profile of Insulin Resistance
2. Trial Evidence in Diabetic Patients
3. Mechanism 1: Insulin Sensitization Reduces De Novo Lipogenesis
4. Mechanism 2: Bile-Acid Binding by Saponin Fractions
5. Effects on Triglycerides — The Largest Lipid Movement
6. Effects on LDL Cholesterol
7. Effects on HDL Cholesterol
8. Comparison to Statins and Berberine
9. Cardiovascular Outcomes — What Can We Actually Say?
10. Integration into a Comprehensive Cardiovascular Protocol
11. Cautions for Lipid-Lowering Use
12. Key Research Papers
13. Connections

Diabetic Dyslipidemia — The Lipid Profile of Insulin Resistance

The lipid abnormality characteristic of type 2 diabetes and metabolic syndrome is not the same as the lipid abnormality of classical familial hypercholesterolemia. The diabetic pattern, sometimes called "atherogenic dyslipidemia" or "lipid triad," has three components:

1. Elevated triglycerides — typically 200-500 mg/dL in poorly controlled type 2 diabetes, sometimes substantially higher
2. Low HDL cholesterol — typically below 40 mg/dL in men and below 50 mg/dL in women with diabetic dyslipidemia
3. Small, dense LDL particles — total LDL cholesterol may be only modestly elevated, but the particle distribution is shifted toward smaller, denser, more atherogenic LDL species (LDL pattern B)

This triad reflects the underlying physiology of insulin resistance. In the insulin-resistant state, the liver receives the wrong metabolic signals from both insulin and substrate flux. The result is overproduction of very-low-density lipoprotein (VLDL), which carries triglycerides into the circulation, where lipoprotein lipase processes them and generates the small dense LDL particles. The same metabolic milieu reduces HDL through accelerated clearance (CETP-mediated cholesteryl ester transfer from HDL to VLDL/LDL in the presence of high triglycerides).

The clinical importance is that this pattern, even when total LDL is not dramatically elevated, contributes substantially to the elevated cardiovascular risk in type 2 diabetes. Patients with diabetic dyslipidemia have approximately 2-4× the cardiovascular event risk of non-diabetic age-matched controls.

Gymnema's lipid effects map onto this pattern with particular relevance. The largest movements are in triglycerides (down) and in the indirect markers of metabolic improvement (HDL up, particle size larger), which is precisely where intervention is most needed in the diabetic lipid phenotype. The total cholesterol and LDL movements are smaller but still meaningful.

For patients with primarily LDL-driven hypercholesterolemia (familial hypercholesterolemia, isolated high LDL), gymnema is not the right tool. A statin is. Gymnema's niche is the diabetic lipid pattern.

Back to Table of Contents

Trial Evidence in Diabetic Patients

The lipid effects of gymnema have been reported as secondary endpoints in essentially all of the trials of gymnema for diabetes. The pattern across trials is remarkably consistent:

• Baskaran 1990 (T2DM trial, 400 mg GS4 daily, 18-20 months) — significant reductions in total cholesterol, triglycerides, and LDL; modest HDL increase. Effects developed gradually over the first 6 months and were sustained through 18-20 months.
• Shanmugasundaram 1990 (T1DM trial, 400 mg GS4 daily, 6-30 months) — similar lipid improvements in the type 1 diabetic group despite the very different underlying disease, suggesting the lipid effects are not dependent on the insulin secretory mechanism
• Subsequent smaller trials and case series — have generally replicated the directional findings, with total cholesterol reductions of 10-15%, triglyceride reductions of 15-25%, and LDL reductions of 10-15% over 12-24 weeks
• Khan 2019 (rodent model of high-fat-diet-induced dyslipidemia) — gymnema extract administration reversed both insulin resistance and dyslipidemia, with associated improvements in liver enzyme patterns consistent with reduced hepatic steatosis. Provides mechanistic support for the insulin-sensitization pathway.
• Various smaller mechanistic studies — have demonstrated bile-acid binding by gymnema saponin fractions, providing biochemical support for the direct cholesterol-lowering pathway

The combined evidence, while not at the rigor level of statin RCTs, is consistent enough to support a clinical claim: chronic gymnema use in diabetic patients produces modest but real improvements in the full lipid panel, with the largest effects on triglycerides.

Back to Table of Contents

Mechanism 1: Insulin Sensitization Reduces De Novo Lipogenesis

The dominant pathway by which gymnema reduces lipid abnormalities is indirect: by improving insulin sensitivity, gymnema reduces the central driver of the diabetic dyslipidemia phenotype.

The mechanism in detail:

1. Insulin-resistant baseline — the liver receives the wrong signals from insulin (resistance) and from chronic high carbohydrate flux. The transcription factor SREBP-1c (sterol regulatory element-binding protein 1c) is constitutively activated. SREBP-1c drives expression of the lipogenic enzymes: acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), and stearoyl-CoA desaturase 1 (SCD1). The result is sustained hepatic de novo lipogenesis — the liver synthesizes fatty acids from carbohydrate substrate at high rates.
2. VLDL overproduction — the newly synthesized fatty acids are packaged with cholesterol and apolipoprotein B-100 into VLDL particles and secreted into circulation. The VLDL output is increased proportionally to the lipogenic flux, driving the elevated serum triglycerides.
3. CETP-mediated HDL depletion — the high circulating triglycerides drive cholesteryl ester transfer protein (CETP) to shuttle cholesteryl esters from HDL to VLDL/LDL particles in exchange for triglycerides. The result is HDL particles depleted of cholesterol (low HDL-C) and triglyceride-enriched LDL particles that are subsequently processed by hepatic lipase to become small, dense LDL.
4. Gymnema intervention — chronic gymnema improves insulin sensitivity through its four-mechanism profile (see the Blood Sugar deep-dive). The flatter postprandial glucose curves reduce postprandial insulin spikes, the improved beta-cell function reduces the chronic hyperinsulinemia, and the reduced visceral adiposity over weeks improves systemic insulin signaling. The net effect is reduced SREBP-1c activation, reduced de novo lipogenesis, reduced VLDL output, lower serum triglycerides, and consequent normalization of HDL and LDL particle size.

This is why the lipid improvements with gymnema take longer than the glycemic improvements: the glycemic effects can be seen within 4-6 weeks (driven by the acute mechanisms), but the lipid improvements develop over 12-24 weeks (driven by the slower chronic reversal of the lipogenic transcriptional program).

The mechanism also explains why gymnema is more effective for triglycerides than for LDL: triglycerides directly reflect VLDL output, which directly reflects de novo lipogenesis. LDL is downstream of multiple processing steps and is influenced by additional factors (LDL receptor expression, PCSK9 levels, dietary cholesterol intake) that gymnema does not strongly affect.

Back to Table of Contents

Mechanism 2: Bile-Acid Binding by Saponin Fractions

The secondary, smaller mechanism by which gymnema lowers cholesterol is direct: triterpene saponins in the gymnema leaf bind bile acids in the small intestinal lumen, interfering with their reabsorption in the terminal ileum.

The physiology: bile acids (cholic acid, chenodeoxycholic acid, and their conjugates) are synthesized in the liver from cholesterol, secreted into the bile, stored in the gallbladder, and released into the small intestine in response to meals (particularly fat-containing meals). They emulsify dietary fats to facilitate digestion. After their work in the small intestine, approximately 95% of bile acids are reabsorbed in the terminal ileum and returned to the liver via the portal circulation — the enterohepatic circulation of bile acids. The liver re-secretes them into the bile for another cycle. The net loss per cycle is only about 5%, which the liver replaces by synthesizing new bile acids from cholesterol.

When a substance interferes with bile acid reabsorption (as bile acid sequestrant drugs like cholestyramine and colesevelam do, and as saponin compounds in various plants do), the loss per cycle increases. The liver compensates by upregulating the cholesterol 7-alpha-hydroxylase (CYP7A1) enzyme, which is the rate-limiting step in bile acid synthesis from cholesterol. The increased bile acid synthesis draws on hepatic cholesterol stores, which are replenished by upregulation of LDL receptor expression, which increases clearance of LDL from circulation, which lowers serum LDL cholesterol.

This is the mechanism by which cholestyramine and colesevelam produce their LDL-lowering effects in pharmacologic use. Gymnema saponins appear to have a milder version of the same effect:

• In vitro — gymnema saponin fractions demonstrably bind cholate and taurocholate in laboratory assays
• In animal models — gymnema administration increases fecal bile acid excretion, consistent with the bile-acid-binding mechanism
• In humans — less direct evidence, but the LDL-lowering effects observed in clinical trials are consistent with a partial bile-acid-binding contribution

The magnitude of the bile-acid-binding contribution is smaller than the insulin-sensitization contribution. It probably accounts for perhaps 20-30% of the total lipid effect, with insulin sensitization accounting for the rest. The bile-acid-binding mechanism is also why gymnema can have lipid effects in non-diabetic patients, where the insulin-sensitization pathway has less room to work — though the magnitude is typically smaller in this population.

Back to Table of Contents

Effects on Triglycerides — The Largest Lipid Movement

Triglycerides are the lipid parameter that responds most reliably and most strongly to gymnema. The mechanism (insulin sensitization reducing hepatic de novo lipogenesis and VLDL output) maps directly onto triglyceride physiology, and the magnitudes seen in clinical trials reflect this.

Typical responses:

• Baseline triglycerides 150-300 mg/dL (mild-moderate elevation) — reductions of 25-40% over 12-24 weeks are typical with GS4 400 mg twice daily
• Baseline triglycerides 300-500 mg/dL (moderate elevation, characteristic of metabolic syndrome) — reductions of 20-30% over the same period
• Baseline triglycerides >500 mg/dL (severe elevation, pancreatitis risk) — gymnema alone is insufficient; aggressive pharmacological intervention (fibrate or high-dose omega-3 prescription) is required, with gymnema only as a complementary adjunct
• Baseline triglycerides <100 mg/dL (already normal) — minimal additional benefit

The largest absolute triglyceride reductions are seen in patients with the worst baseline metabolic disturbance — the same pattern observed with most insulin-sensitizing interventions including dietary carbohydrate restriction, metformin, and the GLP-1 agonist class.

For patients with elevated triglycerides as their primary lipid abnormality, the practical hierarchy of intervention magnitudes (from most to least powerful):

1. Carbohydrate restriction (Mediterranean, low-carb, or ketogenic diet) — can produce 30-60% triglyceride reductions in patients with hypertriglyceridemia
2. Prescription omega-3 ethyl esters (icosapent ethyl, omega-3-acid ethyl esters) — 20-40% triglyceride reduction
3. Fibrates (fenofibrate, gemfibrozil) — 30-50% triglyceride reduction
4. Gymnema (typically with diabetes context) — 15-30% triglyceride reduction
5. Niacin (high-dose, prescription) — 20-30% triglyceride reduction but with significant side-effect burden
6. Berberine — 15-25% triglyceride reduction (similar magnitude to gymnema, somewhat different mechanism)
7. Statins — 10-20% triglyceride reduction (modest effect on triglycerides; statins are primarily LDL-lowering)

The combinations are additive in most cases. Patients with severe diabetic dyslipidemia often benefit from a stack: dietary intervention + prescription omega-3 + gymnema + metformin, with each component contributing 15-25% triglyceride reduction for a combined effect approaching 60-70%.

Back to Table of Contents

Effects on LDL Cholesterol

The LDL-lowering effect of gymnema is smaller than the triglyceride effect and operates through different mechanisms. Typical movements are 10-15% LDL reduction over 12-24 weeks of consistent use, achieved through the combination of bile-acid-binding (the more direct LDL mechanism) and the indirect effects of improved insulin sensitivity on LDL particle size and clearance.

The clinical reality: a 10-15% LDL reduction is modest. A baseline LDL of 160 mg/dL becomes approximately 136-144 mg/dL on gymnema — still elevated but moved in the right direction. For patients whose only concern is mildly elevated LDL, this might be acceptable. For patients with established atherosclerotic cardiovascular disease, familial hypercholesterolemia, or LDL >190 mg/dL, this is inadequate — statin therapy targeting 50% LDL reduction (or PCSK9 inhibition for the highest-risk patients) is the appropriate intervention.

Where gymnema's LDL effect becomes more interesting is in combination with other lipid-lowering interventions:

• With dietary intervention (Mediterranean diet, plant sterol/stanol intake, soluble fiber) — combined effects of 20-30% LDL reduction are achievable, which becomes clinically meaningful
• With berberine — berberine has a more potent LDL-lowering effect (15-25% from monotherapy) through PCSK9 suppression and LDL receptor upregulation; combined with gymnema's additive mechanisms, 25-35% LDL reduction is achievable
• As statin adjunct in patients with statin intolerance — gymnema combined with low-dose statin (often better tolerated than full-dose statin) can sometimes achieve target LDL levels with lower statin doses and fewer side effects

The use case for gymnema as a primary LDL-lowering agent is limited. The use case as a contributor to a multi-component lipid-management strategy in patients with metabolic syndrome or type 2 diabetes is more substantial.

Back to Table of Contents

Effects on HDL Cholesterol

The HDL effects of gymnema are positive but modest. Typical changes are 5-10% HDL increase over 12-24 weeks, driven primarily by the reduction in triglycerides (which reduces CETP-mediated HDL cholesterol depletion).

An HDL change from 35 mg/dL to 38 mg/dL (or from 45 to 49 mg/dL) is small in absolute terms but meaningful epidemiologically — each 1 mg/dL HDL increase is associated with approximately 2-3% lower cardiovascular event risk in observational data, though the recent failure of CETP inhibitor drug programs (which raise HDL substantially through direct CETP blockade but did not improve cardiovascular outcomes) has appropriately cooled enthusiasm for HDL as a direct therapeutic target.

The current understanding is that HDL functional capacity (cholesterol efflux capacity, anti-inflammatory effects) matters more than HDL cholesterol concentration. Gymnema-driven HDL improvements, occurring in the context of broader metabolic improvement (lower triglycerides, better glucose control, improved insulin sensitivity), are reasonably interpreted as part of a genuinely beneficial metabolic shift rather than as an isolated HDL-cholesterol increase that may or may not carry functional benefit.

For patients whose primary lipid abnormality is low HDL with otherwise acceptable LDL and triglycerides, the more impactful interventions are:

• Aerobic exercise (consistently 30-60 minutes/day produces 5-15% HDL increases)
• Weight loss (5% body weight reduction typically increases HDL 5-10%)
• Smoking cessation (typically produces 5-10% HDL increase within months)
• Moderate alcohol intake (small effect, with offsetting risks)
• Reduction of refined carbohydrate intake (improves the HDL/triglyceride relationship)

Gymnema can be a small additional contributor to HDL improvement but should not be the centerpiece of an HDL-improvement strategy.

Back to Table of Contents

Comparison to Statins and Berberine

To position gymnema appropriately in the lipid-lowering landscape:

• Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin) — the most potent LDL-lowering class available, with high-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) producing 50% or greater LDL reductions. Gymnema is not in the same league for LDL-lowering. Statins also have well-established cardiovascular outcome data from large randomized trials (4S, CARE, HPS, JUPITER), which gymnema does not. For patients with established atherosclerotic cardiovascular disease, statin therapy is the standard of care; gymnema is at most an adjunct.
• Berberine — the most potent herbal lipid-lowering agent, with LDL reductions of 15-25% through PCSK9 suppression and LDL receptor upregulation. Comparable triglyceride effects to gymnema. Often considered the "herbal statin" though the mechanism is different from statins (PCSK9 modulation rather than HMG-CoA reductase inhibition). See the Berberine page.
• Gymnema — smaller LDL effect than berberine, comparable triglyceride effect, with the added value of stronger glycemic effects and the unique sweet-taste-blockade application for sugar cravings (see the Sugar Cravings deep-dive)
• Combining berberine + gymnema — the two herbs combine well, with largely orthogonal mechanisms. The combination produces additive lipid effects (perhaps 20-30% LDL reduction combined, 25-40% triglyceride reduction) and is often used in patients seeking herbal-first management of metabolic syndrome before considering pharmacological intervention.
• Ezetimibe — a prescription cholesterol absorption inhibitor that produces 15-20% LDL reduction. Mechanism is somewhat related to the bile-acid-binding pathway of gymnema saponins (both reduce intestinal cholesterol absorption). The two can be used together but the combined effect is not strongly additive.
• PCSK9 inhibitors (evolocumab, alirocumab) — injectable biologics producing 60% LDL reductions in addition to statin therapy, reserved for the highest-risk patients with familial hypercholesterolemia or established cardiovascular disease who are not at goal on statins. Not in the same conversation as gymnema.

The reasonable framework: gymnema is appropriate as part of a comprehensive metabolic-syndrome and type-2-diabetes management approach. It contributes modestly to lipid improvement as part of broader metabolic improvement. It is not appropriate as the primary lipid-lowering agent in patients with substantial cardiovascular risk requiring evidence-based pharmacological intervention.

Back to Table of Contents

Cardiovascular Outcomes — What Can We Actually Say?

The honest answer: we have no randomized controlled trials of gymnema with cardiovascular events or mortality as the primary endpoint. The lipid-lowering effects observed in shorter trials would predict cardiovascular benefit if sustained over years, but this has not been formally demonstrated.

For comparison: the cardiovascular outcome data that drives statin prescribing comes from trials enrolling tens of thousands of patients followed for 5-10 years, with hard endpoints like myocardial infarction, stroke, and cardiovascular mortality. The 4S trial (1994), the CARE trial (1996), the Heart Protection Study (2002), JUPITER (2008), and many others established that statin therapy reduces cardiovascular events by 25-35% over 5-year periods.

No comparable trial has ever been conducted with gymnema, and the economics of such trials (requiring tens of millions of dollars and large patient populations) mean it is unlikely one ever will be. The herbal supplement industry does not have the same regulatory incentives as pharmaceutical companies to pursue outcome trials.

The reasonable inferential framework: the lipid changes observed with gymnema (modest LDL reduction, more substantial triglyceride reduction, modest HDL increase) would predict a modest cardiovascular benefit if sustained over years — perhaps a 10-20% event reduction by extrapolation from the statin and fibrate trial data, though this is unconfirmed. The associated glycemic improvements (HbA1c reduction of 0.5-1.0 percentage points, see the Blood Sugar deep-dive) would add an additional cardiovascular benefit through reduced microvascular and probably macrovascular complications.

Patients with established atherosclerotic cardiovascular disease should not rely on gymnema as their primary preventive intervention. Patients with metabolic syndrome or early type 2 diabetes who want to improve their overall metabolic risk profile while pursuing dietary and lifestyle change can reasonably include gymnema as a low-risk adjunct, with realistic expectations about its magnitude of effect.

Back to Table of Contents

Integration into a Comprehensive Cardiovascular Protocol

The role of gymnema in a metabolically-driven cardiovascular risk-reduction strategy:

• Foundation: dietary pattern — Mediterranean-style or moderate-low-carbohydrate, with emphasis on whole foods, adequate protein, vegetables, legumes, fish, and nuts; reduced refined carbohydrate and sugar intake
• Activity — 150-300 minutes/week of moderate aerobic activity plus 2-3 sessions of resistance training
• Weight management — achieve and sustain BMI in the healthy range; for patients with obesity, even 5-10% weight loss produces meaningful cardiovascular benefit
• Blood pressure management — target <130/80 mmHg for most patients with metabolic syndrome or diabetes
• Glycemic management — HbA1c target generally 6.5-7.0% for most type 2 diabetics, with individualization for older patients or those at risk of hypoglycemia
• Lipid management — statin therapy for patients with established cardiovascular disease, LDL >190 mg/dL, diabetes age 40-75 with risk factors, or 10-year ASCVD risk >7.5-20% per pooled cohort equations. For lower-risk patients managing modestly elevated LDL or triglycerides through dietary and herbal means, gymnema + berberine + diet can be reasonable.
• Gymnema (400 mg GS4 twice daily) — as a low-risk adjunct contributing modest lipid and substantial glycemic improvements alongside the broader protocol
• Other complementary supplements — omega-3 fatty acids (EPA + DHA 2-4 g/day), magnesium glycinate, possibly CoQ10 if on statin therapy
• Smoking cessation — the single highest-impact cardiovascular intervention; supersedes all of the above for patients who smoke

For lipid monitoring, see our Lipid Panel page. For the underlying cardiovascular disease context, see our Atherosclerosis page if available.

Back to Table of Contents

Cautions for Lipid-Lowering Use

• Not a substitute for statin therapy in high-risk patients — the most consequential caution. Patients with established atherosclerotic cardiovascular disease, recent acute coronary syndrome, ischemic stroke, familial hypercholesterolemia, or LDL >190 mg/dL require statin therapy. Substituting gymnema for a statin in this population means accepting a much higher cardiovascular event risk and is not supported by the evidence base.
• Hypoglycemia risk in diabetics on insulin or sulfonylureas — the same caution that applies to gymnema for diabetes management (see the Blood Sugar deep-dive) applies here. Lipid-lowering use does not exempt the patient from the glycemic effects.
• Statin combination — safe and often beneficial. Gymnema does not appear to interfere with statin pharmacokinetics or efficacy. Some patients can achieve their lipid targets with lower statin doses when combined with gymnema, potentially reducing statin side-effect burden.
• Fibrate combination — theoretically synergistic for triglyceride lowering; no evidence of harmful interaction. Routine combination is not typical but is reasonable in selected patients with severe hypertriglyceridemia.
• Bile acid sequestrant combination — theoretically additive (both work in part through bile acid mechanisms); no specific evidence supporting routine combination
• Niacin combination — no specific concerns; both can be used together if needed
• Pregnancy and lactation — insufficient safety data; avoid. Most lipid-lowering therapy is paused during pregnancy regardless of agent.
• Liver disease — no specific hepatotoxicity signal with gymnema, but patients with advanced liver disease should use any new supplement cautiously and with periodic LFT monitoring
• Pancreatitis history — for patients with prior triglyceride-induced pancreatitis, gymnema can be a useful low-risk adjunct to primary triglyceride-lowering therapy (fibrate or prescription omega-3); not a substitute for it

Back to Table of Contents

Key Research Papers

1. Baskaran K et al. (1990). Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. Journal of Ethnopharmacology. Includes lipid endpoints showing significant reductions in total cholesterol, triglycerides, and LDL alongside glycemic improvements. — PubMed
2. Shanmugasundaram ER et al. (1990). Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. Journal of Ethnopharmacology. Type 1 trial showing similar lipid improvements despite different underlying disease. — PubMed
3. Khan F et al. (2019). Gymnema sylvestre extract reverses insulin resistance and ameliorates dyslipidemia in high-fat-diet-induced obese rats. Saudi Journal of Biological Sciences. Mechanistic rodent study linking insulin sensitization to lipid improvements. — PubMed
4. Bishayee A, Chatterjee M (1994). Hypolipidaemic and antiatherosclerotic effects of oral Gymnema sylvestre R. Br. leaf extract in albino rats fed on a high fat diet. Phytotherapy Research. Animal study demonstrating lipid effects independent of diabetes. — PubMed
5. Preuss HG et al. (2004). Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes, Obesity and Metabolism. Includes lipid endpoints. — PubMed
6. Pothuraju R et al. (2014). A systematic review of Gymnema sylvestre in obesity and diabetes management. Journal of the Science of Food and Agriculture. Comprehensive review including lipid endpoints. — PubMed
7. Tiwari P et al. (2014). Gymnema sylvestre for diabetes: from traditional herb to a finished dietary supplement. Indian Journal of Pharmacology. — PubMed
8. Postic C, Girard J (2008). The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes & Metabolism. Background on the SREBP-1c / de novo lipogenesis pathway that gymnema modulates. — PubMed
9. Insull W Jr (2006). Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. Southern Medical Journal. Background on the bile-acid-binding mechanism shared by gymnema saponins and bile acid sequestrant drugs. — PubMed
10. Kong W et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine. Reference for the comparable herbal cholesterol-lowering agent. — PubMed
11. Krauss RM, Siri PW (2004). Metabolic abnormalities: triglyceride and low-density lipoprotein. Endocrinology and Metabolism Clinics of North America. Background on diabetic dyslipidemia. — PubMed
12. Shukla R et al. (2011). Effects of Gymnema sylvestre extract on the regeneration of insulin-producing cells of pancreatic islets in alloxan-induced diabetic rats. Pharmaceutical Biology. Mechanistic study showing combined glycemic and lipid effects. — PubMed

PubMed Topic Searches

• PubMed: gymnema cholesterol/lipid
• PubMed: gymnema triglyceride / VLDL
• PubMed: gymnema saponin bile-acid binding
• PubMed: diabetic dyslipidemia / SREBP-1c
• PubMed: gymnema metabolic syndrome / CV

Back to Table of Contents

Connections

• Gymnema Overview
• Gymnema Benefits Hub
• Gymnema for Blood Sugar
• Gymnema for Sugar Cravings
• Gymnema for Weight Loss
• Berberine (Herbal LDL-Lowering)
• Cinnamon
• Fenugreek
• Chromium
• Lipid Panel
• HbA1c
• Fasting Insulin
• Insulin Resistance
• Diabetes
• Obesity
• Blood Sugar Control

Back to Table of Contents